Effectiveness and Safety of Chinese Medicine to Treat Hand, Foot, and Mouth Disease

NCT01554930 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 230

Last updated 2012-03-15

No results posted yet for this study

Summary

The study is aimed to evaluate the effectiveness and safety of Xiyanping injection,a traditional Chinese medicine (TCM), in the treatment of severe type of hand, foot, and mouth disease (HFMD).

Conditions

  • Hand, Foot, and Mouth Disease

Interventions

DRUG

Western therapy (mannitol, methylprednisolone, immunoglobulin, febrifuge)

Mannitol:0.5-1.0g/kg,q4h to q8h ivgtt; Methylprednisolone:1mg-2mg/kg·d,qd iv; Immunoglobulin:1g/kg; Others:febrifuge,sedative,etc.

DRUG

Xiyanping injection plus western therapy

Xiyanping injection:5-10mg/kg/d (0.2-0.4ml/kg/d),qd ivgtt; Mannitol:0.5-1.0g/kg,q4h to q8h ivgtt; Methylprednisolone:1mg-2mg/kg·d,qd iv; Immunoglobulin:1g/kg; Others:febrifuge,sedative,etc.

Sponsors & Collaborators

  • China Academy of Chinese Medical Sciences

    collaborator OTHER
  • Beijing YouAn Hospital

    collaborator OTHER
  • The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine

    collaborator OTHER
  • Beijing University of Chinese Medicine

    collaborator OTHER
  • Jiangxi Qingfeng Pharmaceutical Co. Ltd.

    lead INDUSTRY

Principal Investigators

  • Li Xiu hui, PhD · Beijing You-An Hospital

  • Zhang Guo liang, PhD · The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine

  • Shi Qin sheng, PhD · Handan Maternal and Child Health Care Hospital

  • Zhu Qin xiong, PhD · Jiangxi Children's Hospital

  • Yang tong, PhD · LiuZhou People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
13 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2010-11-30
Completion
2011-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01554930 on ClinicalTrials.gov